K Number
K220268
Date Cleared
2022-08-23

(204 days)

Product Code
Regulation Number
878.4810
Panel
SU
Reference & Predicate Devices
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
Intended Use

The Picosecond Laser System is intended for use in surgical and aesthetic application in the medical dermatology and general and plastic surgery as follows:

1064nm wavelength:

  • Removal of tattoos on all skin type (Fitzpatrick skin types I-VI) with the following tattoo colors: black, brown, green, blue and purple.
  • Treatment of benign pigmented lesions on Fitzpatrick skin types I-IV.

532nm wavelength:

  • Removal of tattoos on Fitzpatrick skin types I-III with the following tattoo colors: red, yellow and orange.
  • Treatment of benign pigmented lesions on Fitzpatrick skin types I-IV.
Device Description

The Picosecond Laser System consists of a host, a treatment handpiece, a light guide system, a foot switch, power cords and accessories. The host contains a laser, a cooling device, a laser power supply, a control device (including a control device and a LCD) and a protective device. Accessories include a foot switch, a laser protective qlasses, power cords, and a water filling device.

The Picosecond Laser System is a multi-wavelength, pulsed laser system. A key feature of the device is its ability to produce two laser wavelengths (i.e., 1064 nm and 532 nm).

AI/ML Overview

The provided document is a 510(k) summary for a Picosecond Laser System, which is a medical device for dermatological and surgical applications. It is not an AI/ML-driven device, nor does it involve a study aimed at proving the device meets acceptance criteria related to AI/ML performance metrics (e.g., accuracy, sensitivity, specificity).

Therefore, I cannot extract information related to:

  1. A table of acceptance criteria and reported device performance in the context of AI/ML.
  2. Sample sizes for test sets, data provenance, number of experts for ground truth, or adjudication methods for AI/ML performance.
  3. Multi-reader multi-case (MRMC) comparative effectiveness studies.
  4. Stand-alone AI algorithm performance.
  5. Type of ground truth used for AI/ML.
  6. Sample size for the training set or how ground truth for the training set was established for an AI/ML model.

The document focuses on demonstrating substantial equivalence to a predicate device (PicoSecond Nd: YAG Laser System, K200116) through non-clinical testing and comparison of technical specifications. It highlights:

  • Identical Intended Use & Indications for Use between the subject device and the predicate device.
  • Comparable technological parameters such as wavelength, pulse duration, pulse energy, repetition rate, and spot size.
  • Compliance with recognized electrical safety, EMC, laser safety, and biocompatibility standards.
  • Software validation according to FDA guidance for moderate level of concern.
  • Bench testing to ensure the device delivers set energy parameters within specifications.

The document explicitly states:
"No clinical study is included in this submission." (Section 8.0 Clinical Test Conclusion)

Given this, I cannot answer the request in the context of an AI/ML-driven device or study. The information provided pertains to a traditional medical laser system undergoing a 510(k) clearance process based on substantial equivalence, not a performance study of an AI algorithm against specific acceptance criteria.

§ 878.4810 Laser surgical instrument for use in general and plastic surgery and in dermatology.

(a)
Identification. (1) A carbon dioxide laser for use in general surgery and in dermatology is a laser device intended to cut, destroy, or remove tissue by light energy emitted by carbon dioxide.(2) An argon laser for use in dermatology is a laser device intended to destroy or coagulate tissue by light energy emitted by argon.
(b)
Classification. (1) Class II.(2) Class I for special laser gas mixtures used as a lasing medium for this class of lasers. The devices subject to this paragraph (b)(2) are exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 878.9.